A Thai drug’s boost could help an early-stage Palo Alto drug developer change the lives of patients with deadly ALS.
Neuraltus Pharmaceuticals Inc. hopes results from a Phase I trial announced in mid-November will kick its drug into a mid-stage trial early next year of 90 patients or more with amyotrophic lateral sclerosis, better known as Lou Gehrig’s disease.
